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The last observation carried forward (LOCF) analysis overlooks
the meaningfulness of dropout in clinical trials. For antipsychotic
medication dropout is an important outcome since long-term
treatment is often required and dropout may relate to lack of
drug tolerability. OBJECTIVE: The current analysis applies the
“pattern mixture” approach (Shih & Quan, 1997) in which a
composite hypothesis is tested that consists of the probability
that there is a difference in completion rates (d) between two
drugs and the probability that there is a difference in efﬁcacy 
of complete cases (e) [p = p(d) ¥ p(e) ¥ (1- ln(p(d) ¥ p(e)].
METHODS: The pattern-mixture approach was applied to data
from a 53-week randomized, open-label non-inferiority efﬁcacy
trial of risperidone long-acting injectable (RLAI) vs. olanzapine
tablets (OLA) in treating schizophrenia (n = 618) (data on ﬁle
JNJ). RESULTS: LOCF had found a signiﬁcant difference (p =
0.04) on percent of patients in each group who attained clinical
improvement (20% improvement on PANSS total) favoring
RLAI and no signiﬁcance on difference in the continuous
measure of change in PANSS total (p = 0.83). Among completers
there was a greater decline on change in PANSS total favoring
RLAI (Ris -23.6(±14.4); Ola -21.9 (±18.0); 1-tailed p = 0.105).
76% of the RLAI treated patients completed the trial as com-
pared to 70% of the OLA treated patients (one-tailed p = 0.087).
Using the pattern mixture approach the probability for the com-
bined hypothesis of a difference in efﬁcacy in complete cases, and
trial completion, was signiﬁcant (p = 0.05). On clinical improve-
ment, 66.1% of RLAI group both completed the trial and
improved as compared to 53.7% of the olanzapine group (Odds
Ratio [95% Conﬁdence interval]: 1.84 [1.20 :2.82]). CONCLU-
SIONS: LOCF may not capture real-life, clinically important dif-
ferences which can be captured by other approaches.
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OBJECTIVES: This study quantiﬁes excess annual costs associ-
ated with schizophrenia patients in the United States in 2002
from a societal perspective. METHODS: Annual direct medical
costs associated with schizophrenia were estimated separately for
privately (n = 1090) and publicly (Medicaid n = 14,074) insured
patients based on administrative claims data, including a large
private claims database and a State Medicaid database, and com-
pared separately to demographically-geographically matched
control samples (1 case: 3 controls). Medicare costs were
imputed using the Medicare/Medi-Cal dual eligible patients (n =
1491) and published statistics. Excess annual direct non-health
care costs were estimated for law enforcement, homeless shel-
ters, and research/training related to schizophrenia. Excess
annual indirect costs were estimated for four components of pro-
ductivity loss: unemployment, reduced work place productivity,
premature mortality from suicide, and family care giving using
a human capital approach based on market wages. All costs were
adjusted to 2002 dollars using the Consumer Price Index and
were based on the reported prevalence in the National Comor-
bidity Survey Replication. RESULTS: The overall US 2002 cost
of schizophrenia was estimated to be $62.7 billion, with $22.7
billion excess direct health care cost ($7.0 billion outpatient,
$5.0 billion drugs, $2.7 billion inpatient, $8.0 billion long term
care). The total direct non-health care excess costs, including
living cost offsets, were estimated to be $7.6 billion. The total
indirect excess costs were estimated to be $32.4 billion. CON-
CLUSION: Schizophrenia is a debilitating illness resulting in sig-
niﬁcant costs. The indirect excess cost due to unemployment is
the largest component of overall schizophrenia excess annual
costs.
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The prevalence of schizophrenia varies between 0.2–1% and the
cost to treat patients is substantial. Modeling a schizophrenic
population is demanding since schizophrenia is a life long disease
during which patients go through many states and the transition
from one state to another is dependent on the history of patients.
A previously built 1st order Monte Carlo DES model was
adapted to enable 2nd order Monte Carlo simulation. OBJEC-
TIVE: This abstract describes why and how the model was
upgraded from a 1st order Monte Carlo (MC) simulation to a
2nd order MC model. The abstract will describe the choices
made in the design of the model, the internal validity and eval-
uation of its strengths and weaknesses. METHODS: Internal
validity of the model has been explored using data from several
patient databases, as well as literature on a list of variables,
including PANSS, the proportion of patients institutionalized
and costs. Pert, beta, lognormal and uniform distributions have
been used to describe 2nd order uncertainty of relevant variables,
such as PANSS, QALY, risk and costs. RESULTS: The model was
programmed to reﬂect the PANSS at 0 year, 1 year, and 5 years
for patients from the considered databases. The modeled annual
cost per patient and the location distribution were similar to pub-
lished data. Outcomes were expressed in terms of direct medical
costs, number and duration of episodes, PANSS, QALY, GAF,
CGI, SF36 and the SF6 mental component. The uncertainty sur-
rounding the outcomes of costs and effect measures were
assessed with acceptability curves and ellipses. DISCUSSION:
The original DES model was vastly improved with the use of
additional database analyses, additional correlation analyses and
2nd order Monte Carlo simulations. This has resulted in less
emphasis on expert opinion, yielding a partially validated prob-
abilistic model which can be adapted for numerous health care
settings.
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OBJECTIVES: The utility of quality adjusted life years (QALYs)
as an evaluative tool in clinical psychiatric research and drug
trials relating to schizophrenia has rarely been tested due to the
many limitations surrounding its use. The limitations include
lack of comprehensive models of quality of life speciﬁc to schiz-
ophrenia, unavailability of appropriate measures sensitive
enough to pick up small changes that are expected in the course
of the illness, and lack of adequate information about the per-
formance of available instruments. METHODS: This paper
reviews currently available evidence on the use of QALYs in
studies of people with schizophrenia examining the relationship
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between QALY scores and scores on instruments regularly used
in schizophrenia studies such as the PANSS or the CGI, in order
to see if it is possible to construct reliable ‘crosswalks’ between
such clinical measures and the QALY-generating scores.
RESULTS: The limited evidence in the ﬁeld suggests that the cal-
culation of QALYs to quantify the adverse effects of schizo-
phrenia is difﬁcult. Nevertheless, usefulness of such calculation
for a proper estimation of the true burden of schizophrenia
cannot be ignored. Data from a large observational study, fol-
lowing 600 people with schizophrenia over three years, are used
to analyse the correlation between utility-generating scores from
EQ-5D and schizophrenia speciﬁc measures of clinical circum-
stances such as the PANSS, the MADRS, the AIMS measure of
side effects, the Simpson-Angus measure of side effects and the
Barnes Akathisia Rating Scale to see how generic instruments
such as EQ-5D perform in evaluating different health states in
Schizophrenia. CONCLUSIONS: Although the EQ-5D index
does not capture the changes in quality of life associated with
symptoms changes, it may be reasonably valid for calculating
QALYs for patients with schizophrenia.
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OBJECTIVES: 1) To describe the long term evolution of HRQL
of outpatients with schizophrenia, and 2) to analyse its associa-
tion with antipsychotic use. METHODS: SOHO is an ongoing,
3-year, observational study of the treatment of schizophrenia in
ten European countries. The primary objective of SOHO is to
assess the costs and outcomes of treatment of schizophrenia
using antipsychotics. Together with clinical measures, the EQ-
5D (VAS score and tariffs) were administered at baseline, and 3,
6, 12, 18, and 24 months. The ‘panel analysis’ approach was
used, since the outcomes were measured for the distinct post
baseline epochs (0–6, 6–12, 12–18, and 18–24 months of treat-
ment). Multivariate modeling was performed for each epoch,
adjusting for baseline differences among patients. When using
the second and subsequent episodes of patient treatment the
baseline covariates were derived from the covariates collected
when the patient switched treatment. RESULTS: A total of 8109
patients were included in this analysis (44% women; mean age:
40); 24-month retention was 78.47%. Overall, the EQ-5D score
after each period of continuous treatment was: Baseline; mean
0.6 SD 0.32: (0–6 months): 0.76 SD 0.26; (6–12 months): 0.79
SD 0.24 (12–18 months): 0.81 SD 0.23; (18–24 months): 0.82
SD 0.23. Olanzapine-treated patients had statistically higher EQ-
5D utility improvements during the ﬁrst 6 months compared
with risperidone (difference in mean change: 0.041; 95% CI:
0.023–0.06)-, quetiapine (0.032; 0.006–0.059)-, oral (0.081;
0.057–0.105)- and depot typicals (0.077; 0.049–0.105)-treated
patients. No statistical separation was observed between olan-
zapine, clozapine and amilsupride groups. These differences
remain during the 24-month follow-up. CONCLUSIONS:
Antipsychotic treatment is associated with sustained improve-
ment in HRQL. The improvements in EQ-5D scores during the
ﬁrst 6 months for the Olanzapine group were signiﬁcantly higher
than the improvement for other antipsychotics and remaining
thereafter, with the exception of Amilsupride and Clozapine
where no signiﬁcant separation was found.
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OBJECTIVES: To deﬁne criteria for symptoms remission in
depression for reduced versions of the HDRS. METHODS: The
discriminative validity of the HDRS (HDRS-21 and 17 items)
and its shorter scales [Bech Melancholia Scale (BMS-6); Maier
& Philips Severity Scale (MPSS-6); Gibbons et al Depression
Scale (GDS-8); Evans et al Depression Scale (EDS-6)], was
assessed against the Clinical Global Impression of severity (CGI)
in a Spanish multicenter study. The study included 168 depres-
sive patients in ambulatory care. Of these, 118 patients were con-
sidered as clinically unstable (either because of presenting a
new/recurrent disease episode or because of needing an adjust-
ment/change of treatment). After six weeks, those patients were
reassessed by the HDRS and the CGI. The best cut-off points to
discriminate the criterion of clinical remission (CGI score = 1)
were found by using Receiver Operating Characteristic analyses
(ROC). The accuracy of the different versions was assessed by
analysing the area under the ROC curves (AUC). RESULTS: All
versions discriminated at baseline the severity of depression
according to the CGI criterion (all p-values < 0.005 by one-way
ANOVA corrected for multiple comparisons). Also, all versions
discriminated the severity of depression (remission versus no
remission) at six weeks of follow-up (all p-values < 0.0001 by t-
test analyses). The ROC analyses suggested the following cut-off
points to identify remission criteria in our sample (HDRS-21:
<=7; HDRS-17: <=7; BMS: <=2; MPSS: <=3; GDS: <=5; EDS:
<=4). The AUC showed similar accuracy for the HDRS-21,
HDRS-17 and the four shorter versions (AUC range from 0.89
to 0.95, chi2 (ﬁve df) = 8.72, p = 0.12). CONCLUSION: Com-
pared with the canonical versions of the HDRS (21 or 17 items),
shorter versions have showed similar accuracy to deﬁne remis-
sion of depressive symptoms.
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OBJECTIVES: To compare outcomes of patients receiving either
SSRI or SNRI antidepressants for Major Depression in primary-
care settings. METHODS: We analyzed data collected from 
an observational study in 47 primary care facilities in four 
Canadian provinces. Patients meeting DSM-IV-TR criteria for
major depression, >=18 years of age and scoring >=18 on the
HAMD-17 were assigned to groups assessed using HAMD-7 or
HAMD-17. All patients received SSRIs or SNRIs according to
their physician’s preference. Patient outcome was remission
(HAMD-17 <=, or HAMD-7 <=) after 8 treatment weeks.
RESULTS: Of the 337 patients, 159 (47.2%; 66.6% were
females) received SSRIs (citalopram-110, ﬂuoxetine-9, paroxe-
tine-37 and sertraline-3), and 178 (52.8%, 67.4% were females)
received SNRIs (venlafaxine-XR). Mean age was 42.0 ± 13.6 for
SSRIs and 43.7 ± 13.7 for SNRIs (P = 0.60). SSRI-treated
